It has been shown that the presence of TILs in the stromal environment of primary breast tumors may be a key factor contributing to poorer outcomes in patients with triple negative and HER2‐positive breast cancer.4, 5, 8, 9. This evidence concerns the gene ERBB2 and breast cancer.